Targeting the osteoclastogenic cytokine IL-9 as a novel immunotherapeutic strategy in mitigating inflammatory bone loss in post-menopausal osteoporosis.

We observed an increasing trend of IL-9 + Th cells (both percentage and mean fluorescence intensity-MFI) in the BM of Ovx mice at day 15 post-Ovx, which was significantly enhanced at days 30 and 45 ( Figure 1M ) ( Figure S3A-G ).

also in 63,971 other papers